Saturday, October 18, 2008

Pozen shares sink on news of Hatch-Waxman challenge

In the Hatch-Waxman area, Pozen, Inc. announced Par Pharmaceutical Inc. has filed an application with the Food and Drug Administration [FDA] to make a generic version of Treximet, a migraine treatment Pozen developed with GlaxoSmithKline PLC, and shares of Pozen shed nearly 28 percent of their value on 17 Oct. 08

0 Comments:

Post a Comment

<< Home